Deutsche Bank Ag\ Aveo Pharmaceuticals, Inc. Transaction History

Deutsche Bank Ag\

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$8.48 - $14.97 $20,080 - $35,448	2,368 New	2,368 $35,000
Q2 2021 Aug 11, 2021	SELL	$6.21 - $7.45 $289,907 - $347,795	-46,684 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$5.97 - $15.28 $185,864 - $475,712	31,133 Added 200.2%	46,684 $341,000
Q4 2020 Feb 16, 2021	BUY	$5.08 - $6.68 $23,398 - $30,768	4,606 Added 42.08%	15,551 $90,000
Q3 2020 Nov 12, 2020	BUY	$4.16 - $6.26 $19,481 - $29,315	4,683 Added 74.78%	10,945 $65,000
Q2 2020 Aug 13, 2020	BUY	$3.47 - $9.99 $21,729 - $62,557	6,262 New	6,262 $32,000

Ticker AVEO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,676,000
Description
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the ...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.